ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2014
A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 125 citations in OpenAlex.
- Noninvasive molecular imaging signatures of histopathological growth patterns in colorectal cancer liver metastases.Clinical & experimental metastasis · 2026Review
- Imaging Biomarkers in Radiotherapy.Cancers · 2026Review
- Synthesis and Construction of I-124 Labeled Small Molecular Probe for Noninvasive PET Imaging of CAIX Expression.Molecular imaging and biology · 2025Article
- Magnetic resonance imaging to detect tumor hypoxia in brain malignant disease: A systematic review of validation studies.Clinical and translational radiation oncology · 2025Review
- Hypoxia Imaging in Lung Cancer: A PET-Based Narrative Review for Clinicians and Researchers.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Imaging hypoxia for head and neck cancer: current status, challenges, and prospects.Theranostics · 2025Review
- Article
- Article
- Article
- Assessment of hypoxia and oxidative-related changes in a lung-derived brain metastasis model by [EJNMMI research · 2023Article
- Ruthenium-Based Photoactivated Chemotherapy.Journal of the American Chemical Society · 2023Review
- Functional Imaging of Hypoxia: PET and MRI.Cancers · 2023Review
- Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives.Journal of cancer research and clinical oncology · 2022Review
- Hypoxia Imaging As a Guide for Hypoxia-Modulated and Hypoxia-Activated Therapy.Antioxidants & redox signaling · 2022Review
- The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia.Frontiers in pharmacology · 2022Review
- Article
- Imaging carbonic anhydrase IX as a method for monitoring hypoxia-related radioresistance in preclinical head and neck cancer models.Physics and imaging in radiation oncology · 2021Article
- The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial.European journal of nuclear medicine and molecular imaging · 2021Article
- Imaging of Tumor Hypoxia With Radionuclide-Labeled Tracers for PET.Frontiers in oncology · 2021Review
- Imaging methods to evaluate tumor microenvironment factors affecting nanoparticle drug delivery and antitumor response.Cancer drug resistance (Alhambra, Calif.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
unlabelledWe compared the imaging characteristics and hypoxia selectivity of 4 hypoxia PET radiotracers ((18)F-fluoromisonidazole [(18)F-FMISO], (18)F-flortanidazole [(18)F-HX4], (18)F-fluoroazomycin arabinoside [(18)F-FAZA], and (64)Cu-diacetyl-bis(N4-methylsemicarbazone) [(64)Cu-ATSM]) in a single murine xenograft tumor model condition using small-animal PET imaging and combined ex vivo autoradiography and fluorescence immunohistochemistry.
methodsNude mice bearing SQ20b xenograft tumors were administered 1 of 4 hypoxia PET tracers and images acquired 80-90 min after injection. Frozen sections from excised tumors were then evaluated for tracer distribution using digital autoradiography and compared with histologic markers of tumor hypoxia (pimonidazole, carbonic anydrase 9 [CA9]) and vascular perfusion (Hoechst 33342).
resultsThe highest tumor uptake was observed with (64)Cu-ATSM (maximum standardized uptake values [SUV(max)], 1.26 ± 0.13) and the lowest with (18)F-FAZA (SUVmax, 0.41 ± 0.24). (18)F-FMISO and (18)F-HX4 had similar intermediate tumor uptake (SUV(max), 0.76 ± 0.38 and 0.65 ± 0.19, respectively). Digital autoradiographs of hypoxia tracer distribution were compared pixel by pixel with images of immunohistochemistry stains. The fluorinated nitroimidazoles all showed radiotracer uptake increasing with pimonidazole and CA9 staining. (64)Cu-ATSM showed the opposite pattern, with highest radiotracer uptake observed in regions with the lowest pimonidazole and CA9 staining.
conclusionThe fluorinated nitroimidazoles showed similar tumor distributions when compared with immunohistochemistry markers of hypoxia. Variations in tumor standardized uptake value and normal tissue distribution may determine the most appropriate clinical setting for each tracer. (64)Cu-ATSM showed the highest tumor accumulation and little renal clearance. However, the lack of correlation between (64)Cu-ATSM distribution and immunohistochemistry hypoxia markers casts some doubt on the hypoxia selectivity of (64)Cu-ATSM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.